.7576 each, funded alongside cash from existing reserves plus new acquisition debt facilities. Against assessed maintainable EBIT of .0m, the implied EV/EBIT multiples are 4.3x on upfront consideration alone, 4.9x with Year 1, 5.4x with Years 1–2, and 5.9x if all three hurdles are met. The deal is expected to be ~25% EPS accretive on a pro forma basis, benchmarked against Vysarn's forecast FY2026 NPBT (disclosed to ASX 2 March 2026) a…","url":"https://www.strawman.com/forums/topic/13242","discussionUrl":"https://www.strawman.com/forums/topic/13242","author":{"@type":"Person","name":"Ray Hemphill","alternateName":"raymon68","url":"https://www.strawman.com/members/raymon68"},"isPartOf":{"@type":"WebSite","name":"Strawman","url":"https://www.strawman.com"},"description":"Shares for the upfront and Year 1 tranches are valued at .7576 each, funded alongside cash from existing reserves plus new acquisition debt facilities. Again…","datePublished":"2026-06-04T19:44:44+10:00"}